Balancing Effective Treatments With Potential Threats: The Impact of Biologic Agent Use on Tuberculosis Development in Children With Chronic Inflammatory Disorders

International Journal of Rheumatic Diseases, Journal Year: 2025, Volume and Issue: 28(2)

Published: Feb. 1, 2025

We aimed to investigate the frequency and clinical characteristics of tuberculosis in pediatric patients receiving both anti-TNF-alpha other biological agents. The data 270 who used agents due rheumatologic diseases inflammatory bowel disease (IBD) were followed between January 2021 October 2023 retrospectively collected from their files. Of patients, 138(51.1%) female, 132(48.9%) male. mean age at diagnosis was 107 months (min 8-max 215 months). Patients most commonly for juvenile idiopathic arthritis (JIA) (191 70.7%), by autoinflammatory (49 patients) IBD (26 9.6%). Treatments included adalimumab (97 35.9%), etanercept (85 31.5%), canakinumab (33 12.2%), tocilizumab (31 11.5%), infliximab (16 5.9%), anakinra (5 1.9%), tofacitinib (2 0.7%), rituximab (1 patient, 0.4%). During follow-up, latent infection (LTBI) developed 5 (1.9%) patients. Three these had JIA (using adalimumab, tocilizumab), one Familial Mediterranean Fever canakinumab), adalimumab). duration agent treatment until LTBI development 14.6 6-max 29 Tuberculosis diagnosed two Both up IBD. One with miliary after treatment, while lymphadenitis treatment. Quadruple anti-tuberculosis therapy initiated use has revolutionized course chronic childhood. However, monitoring risk is crucial.

Language: Английский

---

The antiviral potential of Vγ9Vδ2 T cells: Therapeutic implications for immunocompromised adult and pediatric hosts

International review of cell and molecular biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Infectious Diseases and Secondary Antibody Deficiency in Patients from a Mesoregion of São Paulo State

Published: March 4, 2024

Our aim was to determine the secondary antibody deficiency profiles of patients in a mesoregion São Paulo state, Brazil, focusing on infectious diseases. Demographic characteristics, clinical and laboratory data were obtained from electronic files; infections classified as organ-specific graded mild, moderate, life-threatening, fatal. Non-Hodgkin lymphoma (NHL) accounted for 30% patients, nephrotic syndrome (NS) 25%; chronic lymphocyte leukemia 20%, multiple myeloma 15%. Patients with NS younger than those other groups, hypo-γ-globulinemia detected 94.1%, IgG <400 mg/dL 60.0%, IgA <40 55.0%, CD19 <20 cells/mm3 30.0%. One hundred one found; 82.1% mild or 7.9% 1.9% Respiratory tract more prevalent (41.5%), pneumonia 19.8%. Lower levels found compared NHL (P=0.0001). Most progressed after treatment immunosuppressants, moderate predominant. These therapies are increasing different diseases, therefore monitoring may help identify at high risk severe complications, antibiotic prophylaxis treatment, immunoglobulin replacement

Language: Английский

---

Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population

Advances in Clinical Neuroscience & Rehabilitation, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

---

Infectious Diseases and Secondary Antibody Deficiency in Patients from a Mesoregion of São Paulo State, Brazil

Tropical Medicine and Infectious Disease, Journal Year: 2024, Volume and Issue: 9(5), P. 104 - 104

Published: May 6, 2024

Our aim was to determine the secondary antibody deficiency (SAD) profiles of patients in a mesoregion São Paulo state, Brazil, focusing on infectious diseases. Demographic characteristics, and clinical laboratory data were obtained from electronic files; infections classified as organ-specific graded mild, moderate, life-threatening, fatal. Non-Hodgkin’s lymphoma (NHL) accounted for 30% patients, nephrotic syndrome (NS) 25%, chronic lymphocyte leukemia 20%, multiple myeloma 15%. Patients with NS younger than those other groups, hypo-γ-globulinemia detected 94.1%, IgG < 400 mg/dL 60.0%, IgA 40 55.0%, CD19 20 cells/mm3 30.0%. One hundred one found; 82.1% mild or 7.9% 3.0% Respiratory tract more prevalent (41.5%), pneumonia 19.8%. Lower levels found compared NHL (p = 0.0001). Most progressed SAD after treatment immunosuppressants, moderate predominant. These therapies are increasing different diseases; therefore, monitoring may help identify at high risk severe complications, antibiotic prophylaxis treatment, immunoglobulin replacement.

Language: Английский

---

Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends

Recent Advances in Inflammation & Allergy Drug Discovery, Journal Year: 2024, Volume and Issue: 19(1), P. 31 - 45

Published: July 11, 2024

Over the world, millions of individuals suffer from psoriasis, a chronic inflammatory skin disease. It is caused by multifaceted mixture environmental, immunological, and genetic factors. This review explores many aspects where introduction gives context background, emphasizing prevalence difficulties that people encounter with this dermatological ailment. Further, pathogenesis complex systems involving immunological dysregulation, susceptibility, triggers are clarified, providing insights into disease's fundamental mechanisms. Examining drugs shows how, over time, therapy modalities have evolved, moving traditional topical treatments to biologics small molecules. The continuous efforts control symptoms, reduce inflammation, improve patient outcomes highlighted in section. Furthermore, thorough patents reveals creative advancements made sector, highlighting encouraging treatment potential paths forward. manuscript article based on various research articles. We summarized salient features findings different articles prepared manuscript.

Language: Английский

---

Stepping up our game with secondary immune deficiency

Annals of Allergy Asthma & Immunology, Journal Year: 2023, Volume and Issue: 130(6), P. 693 - 694

Published: June 1, 2023

Language: Английский

---